Skip to main content
Fig. 3 | Health and Quality of Life Outcomes

Fig. 3

From: Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study

Fig. 3

Outcomes from –2 to + 2 days around infusion in patients with PNH treated with ravulizumab (N = 28). a Resting heart rate. b Daily step count. c Sleep duration. bpm beats per minute, PNH paroxysmal nocturnal hemoglobinuria, SD standard deviation, dashed lines represent US general population normative values. Data presented as locally estimated scatter plot smoother. Four patients were excluded from the analysis: two patients who withdrew and two who were considered to be outliers (daily number of steps > 2 SD from the mean). General population normative values: resting heart rate, range 50–80 bpm (mean 65.5 bpm) [30]; daily step count, 7271 [31]; sleep duration, mean (SD), 7.2 (1.0) hours [32]

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us